The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells
Open accessAbstract
Efficient T cell activation is dependent on the intimate contact between antigen-presenting cells (APCs) and T cells. The engagement of the B7 family of molecules on APCs with CD28 and CD152 (cytotoxic T lymphocyte–associated antigen 4 [CTLA-4]) receptors on T cells delivers costimulatory signal(s) important in T cell activation. We investigated the dependence of pathologic cellular activation in psoriatic plaques on B7-mediated T cell costimulation. Patients with psoriasis vulgaris received four intravenous infusions of the soluble chimeric protein CTLA4Ig (BMS-188667) in a 26-wk, phase I, open label dose escalation study. Clinical improvement was associated with reduced cellular activation of lesional T cells, keratinocytes, dendritic cells (DCs), and vascular endothelium. Expression of CD40, CD54, and major histocompatibility complex (MHC) class II HLA-DR antigens by lesional keratinocytes was markedly reduced in serial biopsy specimens. Concurrent reductions in B7-1 (CD80), B7-2 (CD86), CD40, MHC class II, CD83, DC–lysosomal-associated membrane glycoprotein (DC-LAMP), and CD11c expression were detected on lesional DCs, which also decreased in number within lesional biopsies. Skin explant experiments suggested that these alterations in activated or mature DCs were not the result of direct toxicity of CTLA4Ig for DCs. Decreased lesional vascular ectasia and tortuosity were also observed and were accompanied by reduced presence of E-selectin, P-selectin, and CD54 on vascular endothelium. This study highlights the critical and proximal role of T cell activation through the B7-CD28/CD152 costimulatory pathway in maintaining the pathology of psoriasis, including the newly recognized accumulation of mature DCs in the epidermis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Sallusto, F., Cella, M., Danieli, C., & Lanzavecchia, A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.389 · Cited by 2,500
Dustin, M. L., Rothlein, R., Bhan, A. K., Dinarello, C. A., & Springer, T. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.1.245 · Cited by 2,450
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Bevilacqua, M. P., Stengelin, S., Gimbrone, M. A., & Seed, B. (1989) · Science · doi:10.1126/science.2466335 · Cited by 2,005
Reciprocal Control of T Helper Cell and Dendritic Cell Differentiation
Rissoan, M.-C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., Malefyt, R. D. W., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.283.5405.1183 · Cited by 1,846
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Self-citationActivation of human dendritic cells through CD40 cross-linking.
Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., & Banchereau, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1263 · Cited by 1,317
The Role of the CD28 Receptor During T Cell Responses to Antigen
Linsley, P. S., & Ledbetter, J. A. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001203 · Cited by 1,298
Self-citationT Lymphocyte Costimulation Mediated by Reorganization of Membrane Microdomains
Viola, A., Schroeder, S., Sakakibara, Y., & Lanzavecchia, A. (1999) · Science · doi:10.1126/science.283.5402.680 · Cited by 938
Cited by
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Self-citationCo-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
Steinman, R. M., & Nussenzweig, M. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231606698 · Cited by 1,166
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.59 · Cited by 1,129
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Self-citationEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Costimulation Blockade with Belatacept in Renal Transplantation
Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050085 · Cited by 861
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Self-citationPsoriasis pathophysiology: current concepts of pathogenesis
Krueger, J. G., & Bowcock, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031120 · Cited by 523
Self-citationCrystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., & Mosyak, L. (2001) · Nature · doi:10.1038/35069118 · Cited by 489
Getting under the skin: the immunogenetics of psoriasis
Bowcock, A. M., & Krueger, J. G. (2005) · Nature Reviews Immunology · doi:10.1038/nri1689 · Cited by 484
Self-citationRecent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
Kamradt, T., & Mitchison, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440907 · Cited by 457
Lowes, M. A., Chamian, F., Abello, M. V., Fuentes-Duculan, J., Lin, S.-L., Nussbaum, R., Novitskaya, I., Carbonaro, H., Cardinale, I., Kikuchi, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509736102 · Cited by 456
Self-citationInterleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
Ghoreschi, K., Thomas, P., Breit, S., Dugas, M., Mailhammer, R., van Eden, W., van der Zee, R., Biedermann, T., Prinz, J., Mack, M., et al. (2003) · Nature Medicine · doi:10.1038/nm804 · Cited by 453
Immunopathogenic mechanisms in psoriasis
GUDJONSSON, J. E., JOHNSTON, A., SIGMUNDSDOTTIR, H., & VALDIMARSSON, H. (2003) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02310.x · Cited by 397
New insights of T cells in the pathogenesis of psoriasis
Cai, Y., Fleming, C., & Yan, J. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.15 · Cited by 389
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Guilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F.-X., Lecron, J.-C., & Morel, F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902464 · Cited by 353
Molecular Dissection of Psoriasis: Integrating Genetics and Biology
Elder, J. T., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Stuart, P. E., Tejasvi, T., Voorhees, J. J., Abecasis, G. R., & Nair, R. P. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.319 · Cited by 320
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30176 · Cited by 300
Zhou, X., Krueger, J. G., Kao, M.-C. J., Lee, E., Du, F., Menter, A., Wong, W. H., & Bowcock, A. M. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00157.2002 · Cited by 295
Self-citationLew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Self-citationCarlin, C. S., Feldman, S. R., Krueger, J. G., Menter, A., & Krueger, G. G. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.09.014 · Cited by 278
Self-citationCTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
Marcil, I., & Stern, R. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06179-7 · Cited by 258
Metadata
- Authors
- Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., & Krueger, J. G.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2000-09-05
- Volume
- 192
- Issue
- 5
- Pages
- 681-694
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2131136878
- Cited by
- 318
- References
- 60
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.